Stikeman Elliott provides a full range of business law services to biotechnology and life science-based companies and their investors. We also advise companies in other industries on biotech-related matters. From biotech start-ups to multinational corporations, our lawyers provide expert advice on mergers, acquisitions, financings, securities, taxation, employment, licensing, strategic contracts and joint ventures, patent portfolio development, copyright and trade-mark, issues, and much more. We also have significant experience conducting reviews of intellectual property assets, contractual obligations, corporate structures, and litigation portfolios of biotech companies in support of mergers and acquisitions, financing, licensing and other major business transactions.

With offices located in cities that dominate medical research and health-product manufacturing, we have developed extensive expertise in this sector. We have acted or currently act for companies and individuals in the health-care sector, including pharmaceutical companies, biotechnology companies, researchers, health-care facilities based in Canada, the U.S., and elsewhere, and other organizations in the health-care sector. We have developed particular expertise in biotechnology and pharmaceutical issues in Montréal, reflecting that city's historical importance as a centre for the industry, and in Ottawa in the area of regulation. Our regulatory lawyers assist a variety of clients, including large multinational drug companies, in attaining regulatory approval from Health Canada and other government agencies on new drug submissions, labelling, good manufacturing practices, and non-prescription drugs.